Investors

Roche Full Year Results 2025

Roche has published its Full Year Results for 2025 prior to the opening of the Swiss Stock Exchange on Thursday, 29 January 2026.

Please click here to watch the replay of the webinar
Presentation download
Presentation download with appendix

A blue-gloved hand delicately holds a small pink container with a QR code. Nearby are green, blue, and yellow containers on a white surface, indicating a scientific setting.

Roche’s Virtual Neurology/ACTRIMS Investor Event

Monday, 9 February at 16:30 CET

More details

A gloved hand in a lab coat holds a small, clear vial against a blurred background of lab equipment, conveying a scientific and clinical setting.

39 million

patients were treated with Roche medicines in 2025

31 billion

Roche Diagnostic tests were delivered to customers worldwide in 2025

+11%

Core earnings per share growth at Constant Exchange Rates in 2025 (Core EPS 19.46 CHF - diluted)

Product Development Pipeline

Read the letter to shareholders

Our two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.

Dr Thomas Schinecker

CEO Roche Group

Investor updates

View all updates

View ad-hoc announcements

Upcoming Investor events

View all events

Roche’s Virtual Neurology/ACTRIMS Investor EventInvestors

February 09, 2026 at 16:30 CET

Add to calendar

TD Cowen 4th Annual Healthcare ConferenceInvestors

March 03, 2026 at 08:00 EST | Boston, US

Add to calendar

UBS European Healthcare ConferenceInvestors

March 03, 2026 at 08:00 GMT | London, UK

Add to calendar

Barclays Global Healthcare ConferenceInvestors

March 10, 2026 at 08:00 GMT | Miami, US

Add to calendar

2026 Annual General Meeting (tentative)Investors

March 10, 2026 at 10:30 CET | Basel, Switzerland

Add to calendar

BNP Paribas Exane Healthcare ConferenceInvestors

March 24, 2026 at 08:00 GMT | London, UK

Add to calendar

Goldman Sachs Biopharma Innovation SummitInvestors

March 25, 2026 at 08:00 GMT | London, UK

Add to calendar

Roche 1st Quarter Sales 2026 (virtual event)Investors

April 23, 2026 at 14:00 CEST | Basel, Switzerland

Add to calendar

Berenberg Diagnostics ConferenceInvestors

May 06, 2026 at 08:00 BST | London, UK

Add to calendar

Latest reports

Annual report 2025Investors

Smiling scientist in a lab coat and safety glasses holds a pipette in a modern laboratory. The setting conveys focus and innovation.

Half-year report 2025Investors

Finance Information Tool

Reporting

Download center

Share and Bond information

US investors

ESG Index

Investor relations team contacts

Do you need to get in touch with us? Reach out to our investor relations team with your enquiries.

View investor contact detail

Discover More

Roche Diagnostics news

Follow the most recent updates from our Diagnostics business

Genentech

Genentech has been delivering on the promise of biotechnology for over 35 years.

Sustainability at RocheAbout Roche

At Roche, our ambition lies not only in transforming healthcare, but also in our contributions to environmental protection, supply chain sustainability, social commitment and philanthropy.

Positions, policies & downloadsAbout Roche

Download our policies, guidelines, positions and other documents.

Frequently Asked QuestionsInvestors

We answer the Roche investors-related most frequently asked questions

PartneringInnovation

At Roche Partnering, we are passionate about science: yours and ours. Through partnerships, we hope that together we can build a better future with medicines that make a real difference to patients.